Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary.... Research Beam Model: Research Beam Product ID: 17818 2500 USD New
Global Hypertension Drugs Market 2014-2018
 
 

Global Hypertension Drugs Market 2014-2018

  • Category : Pharmaceuticals
  • Published On : April   2014
  • Pages : 65
  • Publisher : Technavio
 
 
 

About Hypertension Drugs

Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. 

TechNavio's analysts forecast the Global Hypertension Drugs market will grow at a CAGR of 1.2 percent over the period 2013-2018.

Covered in this Report

The Global Hypertension Drugs market can be categorized into eight segments: Diuretics, ACE Inhibitors, ARBs, CCB, Beta Blockers, Alpha Blockers, Vasodilators, and Renin Inhibitors. To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension.

TechNavio's report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas 

• EMEA        

• APAC

Key Vendors

• Actelion Ltd.

• AstraZeneca plc 

• Boehringer Ingelheim GmbH 

• Novartis AG 

• Pfizer Inc.

• Sanofi SA

Other Prominent Vendors

 

• Bayer AG 

• Daiichi Sankyo Co. Ltd.

• Forest Laboratories Inc.

• Merck & Co. Inc.

• Takeda Pharmaceutical Co. Ltd.

• United Therapeutics Corp.

• Valeant Pharmaceuticals International Inc.

• XOMA LLC 

Key Market Driver

• Increase in Aging Population.

• For a full, detailed list, view our report.

Key Market Challenge

• Increasing Number of Patent Expirations.

• For a full, detailed list, view our report.

Key Market Trend

• Increasing Focus on Combination Therapies. 

• For a full, detailed list, view our report.

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



 


01. Executive Summary

02. List of Abbreviations

03. Scope of the Report


03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape


06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Rate of Incidence and Prevalence

07.1.1 Americas

07.1.2 The APAC Region

07.1.3 Europe

08. Late Stage Pipeline Snapshot

09. Market Segmentation by Mechanism of Action

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape


18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Actelion Ltd.

19.1.1 Business Overview

19.1.2 Key Information

19.1.3 SWOT Analysis

19.2 AstraZeneca plc

19.2.1 Business Overview

19.2.2 Key Information

19.2.3 SWOT Analysis

19.3 Boehringer Ingelheim GmbH

19.3.1 Business Overview

19.3.2 Business Segmentation

19.3.3 Key Information

19.3.4 SWOT Analysis

19.4 Novartis AG

19.4.1 Business Overview

19.4.2 Business Segmentation

19.4.3 Key Information

19.4.4 SWOT Analysis

19.5 Pfizer Inc.

19.5.1 Business Overview

19.5.2 Business Segmentation

19.5.3 Key Information

19.5.4 SWOT Analysis

19.6 Sanofi SA

19.6.1 Business Overview

19.6.2 Business Segmentation

19.6.3 Key Information

19.6.4 SWOT Analysis

20. Other Reports in this Series



List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Hypertension Drugs Market 2013-2018 (US$ billion)

Exhibit 3: Global Hypertension Drugs Market Segmentation by Mechanism of Action

Exhibit 4: Global Hypertension Drugs Market 2013

Exhibit 5: Global Hypertension Drugs Market by Geographical Segmentation 2013

Exhibit 6: Global Hypertension Drugs Market by Vendor Segmentation 2013

Exhibit 7: Business Segmentation of Boehringer Ingelheim GmbH

Exhibit 8: Business Segmentation of Novartis AG

Exhibit 9: Business Segmentation of Pfizer Inc.

Exhibit 10: Business Segmentation of Sanofi SA



PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT